These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28738449)

  • 1. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
    Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
    Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
    Mahmood I
    Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.
    Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K
    J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease.
    Malik PRV; Yeung CHT; Ismaeil S; Advani U; Djie S; Edginton AN
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S52-S62. PubMed ID: 33205424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.
    Peng J; Ladumor MK; Unadkat JD
    Drug Metab Dispos; 2021 Oct; 49(10):929-937. PubMed ID: 34315779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
    Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
    Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
    De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
    Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.
    Xia B; Heimbach T; Gollen R; Nanavati C; He H
    AAPS J; 2013 Oct; 15(4):1012-24. PubMed ID: 23835676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment.
    Tan SPF; Scotcher D; Rostami-Hodjegan A; Galetin A
    Clin Pharmacol Ther; 2022 Sep; 112(3):643-652. PubMed ID: 35569107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.
    Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D
    CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.
    Franchetti Y; Nolin TD
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S36-S51. PubMed ID: 33205428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.
    Tan ML; Zhao P; Zhang L; Ho YF; Varma MVS; Neuhoff S; Nolin TD; Galetin A; Huang SM
    Clin Pharmacol Ther; 2019 Mar; 105(3):719-729. PubMed ID: 30074626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling.
    Dubinsky S; Malik P; Hajducek DM; Edginton A
    Clin Pharmacokinet; 2022 Jul; 61(7):997-1012. PubMed ID: 35508593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.
    Bergman A; Bi YA; Mathialagan S; Litchfield J; Kazierad DJ; Pfefferkorn JA; Varma MVS
    Clin Pharmacol Ther; 2019 Oct; 106(4):792-802. PubMed ID: 30919935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.
    Scotcher D; Jones CR; Galetin A; Rostami-Hodjegan A
    J Pharmacol Exp Ther; 2017 Mar; 360(3):484-495. PubMed ID: 28057840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs.
    Coppola P; Kerwash E; Cole S
    J Clin Pharmacol; 2022 Sep; 62 Suppl 1():S129-S139. PubMed ID: 36106785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
    Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
    Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.
    Sayama H; Takubo H; Komura H; Kogayu M; Iwaki M
    AAPS J; 2014 Sep; 16(5):1018-28. PubMed ID: 24912798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
    Feng B; Varma MV
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.